UK GlaxoSmithKline drugmaker to invest USD216 m
(MENAFN) UK-based Drugmaker GlaxoSmithKline will invest USD216 million in Africa by 2018 as it bets on the importance of the continent in driving long-term demand for medicine, according to Oman Observer
The company has showed interest in Africa, given improved economic growth and rising demand for treatments against chronic diseases
The rise of non-communicable diseases (NCDs) like heart and lung disorders, diabetes and cancer is changing the market for drugs in Africa and increasing demand for new products beyond treatments for acute infections
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.